Mar 12, 2012 | Seeking Alpha
Will Medgenics Become The Next Hepatitis-C Take Over Candidate?
Interest in the hepatitis-C space has been hot since the euphoria of Big Pharma's acquisition of Inhibitex and others began to spread further in early January.
A Biotech's Path To Acquisition
During the final days of 2011, Steve Worland, Ph.D., and his 26 colleagues at Anadys Pharmaceuticals transferred their work - and the company's assets in hepatitis C drug development - to Roche Holding AG.
Inhibitex Deal Bags Investors A Huge Premium
On Saturday evening, it was announced that Bristol-Myers Squibb has agreed to acquire Inhibitex Inc.
Wall Street's roller-coaster year ends quietly
It was a lackluster trading day with many traders and invest ... [read story] Chris Martin's sleepless nights Singer Chris Martin is troubled by sleepless nights, so much so that he has sought the help of a therapist to solve the dilemma.